Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F2	Mar 2, 2018	J	152,062	$0.00	A	152,062	I	By David J. Collier
Common Stock^F3	holding	—	—		—	2,395,068	I	By Presidio Partners 2007, L.P.
Common Stock^F4	holding	—	—		—	61,410	I	By Presidio Partners 2007 (Parallel), L.P.

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

F1Pro rata distribution from Velocity Pharmaceutical Development, LLC, of which the reporting person is a non-managing member.
F2Securities directly held by David J. Collier, M.D., a general partner of Presidio GP (as defined below), which is the sole general partner of Presidio Partners (as defined below).
F3Securities directly held by Presidio Partners 2007, L.P. ("Presidio Partners"). Presidio Partners 2007 GP, L.P. ("Presidio GP") is the sole general partner of Presidio Partners. David Collier, M.D., James Watson and Faysal Sohail are the general partners of Presidio GP, and may be deemed to have voting control and investment power over the securities held by Presidio Partners, but disclaim beneficial ownership of the securities held by Presidio Partners, except to the extent of their pecuniary interest therein.
F4Securities directly held by Presidio Partners 2007 (Parallel), L.P. ("Presidio Parallel"). Presidio GP is the sole general partner of Presidio Parallel. David Collier, M.D., James Watson and Faysal Sohail are the general partners of Presidio Parallel, and may be deemed to have voting control and investment power over the securities held by Presidio Parallel, but disclaim beneficial ownership of the securities held by Presidio Parallel, except to the extent of their pecuniary interest therein.